Tesamorelin: the complete research guide.

Tesamorelin is a 44-amino-acid copy of growth-hormone-releasing hormone. It's the only peptide of its kind the FDA has approved. It ran two large Phase III trials, all in one narrow group: adults with HIV-associated lipodystrophy. Outside that group you'll find no controlled human data. We treat it as the yardstick for this class.

Tesamorelin matters because it sets the bar. Put it beside CJC-1295 or ipamorelin. You can see exactly what those two are missing. Tesamorelin is not mechanically unique. It just ran the trials.

This guide covers what tesamorelin is. Then what the FDA trials showed. Then what later research added. Then where the negative trials sit. And last, what it actually costs to access the drug in 2026.

What is tesamorelin?

Tesamorelin is a synthetic copy of a natural pituitary signal. That signal is growth-hormone-releasing hormone. Tesamorelin is 44 amino acids long. The key trick is a chemical tweak on one end. It protects the peptide from the enzyme DPP-4. DPP-4 would destroy the natural version within minutes.

That tweak stretches how long the peptide stays active in blood. In healthy adults it runs roughly 26-38 minutes. Long enough to do its job. Short enough to keep the body's natural pulsing rhythm of growth hormone release.

The mechanism is straightforward. Tesamorelin docks onto a binding site on the pituitary. The pituitary releases growth hormone in pulses. Growth hormone then tells the liver to make IGF-1. IGF-1 is insulin-like growth factor-1. It is the main builder of tissue.

Pulsing matters. Synthetic growth hormone produces a flat, continuous level in blood. Tissues respond less efficiently to that than to natural pulses. Tesamorelin keeps the pulsatile rhythm.

That's why it works at growth-hormone levels a healthy body would produce on its own. Injected growth hormone pushes levels well past that range.

The pivotal Phase III data: what the FDA approved

The FDA approved tesamorelin in 2010 on two large randomized placebo-controlled trials. Every participant had HIV-associated lipodystrophy. That's a body-composition disorder: visceral fat around the organs piles up while the fat under your skin wastes away.

The trials measured visceral fat on CT scans. At 26 weeks, tesamorelin reduced visceral fat by 15-18% vs placebo. Waist measurements decreased. Tissue-building signals rose, consistent with the mechanism.

One finding stands out: the effect was selective. Tesamorelin cut visceral fat without stripping fat from under the skin. That mattered, because these participants had already lost subcutaneous fat to the disease. Pulsatile growth hormone mobilizes visceral fat first, and that selectivity underpins the labeled use.

The SV formulation, approved in 2019, is the same active compound at a higher concentration. The injected volume is smaller. The pharmacology is unchanged.

HIV-associated fatty liver: a year of paired biopsies

The most-cited follow-up trial enrolled 61 study participants with HIV-associated fatty liver disease at Massachusetts General Hospital. It ran 12 months with paired liver biopsies at start and end.

The findings: tesamorelin reduced liver fat. More important, it stopped fibrosis from progressing against placebo. Fibrosis is scarring, and it's a hard endpoint rather than a surrogate.

Three substudies spun off the same dataset and showed how tesamorelin works in liver tissue:

• Gene expression in the liver. Fourman and colleagues found tesamorelin turned up energy-production genes and turned down inflammation genes in paired biopsies (Fourman et al., 2020, JCI Insight).
• Blood proteomics. A targeted study showed drops in VEGFA, TGFB1, and CSF1. The drops tracked with better liver scores (Fourman et al., 2021, Scientific Reports).
• Immune activation. A Clinical Infectious Diseases paper reported tesamorelin lowered 13 immune-activation proteins, including chemokines, cytokines, and T-cell markers (Stanley et al., 2021).

Our reading: tesamorelin doesn't just move fat. It quiets liver inflammation and immune activation too. Whether that carries over to fatty liver disease without HIV, now called MASLD, is the open question driving current research.

The 2024 integrase-inhibitor sub-analysis

Modern HIV treatment starts with integrase inhibitors, drugs like dolutegravir and bictegravir. Those regimens are linked to weight gain and visceral fat. A 2024 sub-analysis asked whether tesamorelin still worked in participants taking them.

Russo and colleagues analyzed 38 participants and reported:

• Median visceral fat change: −25 cm² on tesamorelin vs +14 cm² on placebo
• Liver fat: −4.2% on tesamorelin vs −0.5% on placebo
• Improved trunk-to-limb fat ratio in the treatment arm
• Hyperglycemia rates similar between groups

That sub-analysis matters because integrase inhibitors are the dominant HIV treatment today. Tesamorelin held its activity in the population most likely to encounter it.

Fat quality, not just quantity

One recent paper analyzed CT data from 341 participants. Lake and colleagues looked at fat density, not just fat area, writing in AIDS in 2021.

Higher density on CT means healthier, smaller fat cells. Lower density means swollen, stressed fat cells that pump out inflammation. Tesamorelin increased fat density independent of changes in fat area.

The implication: how much fat you carry and how healthy that fat is are two different measures. Tesamorelin appears to shift fat toward a healthier cellular pattern even when the volume doesn't change. The authors flag that as relevant to cardiometabolic risk.

Where this falls short: the cognition trial

An earlier 2012 study by Baker and colleagues had hinted tesamorelin might help cognition in older adults with mild impairment. The 2025 Ellis trial is the most rigorous follow-up we've seen. It didn't confirm the signal.

For us, this is what distinguishes tesamorelin from grey-market peptides. Someone actually ran the trial that could have gone either way. It went negative, and that's now part of our record.

Adverse events and labeled contraindications

Tesamorelin's safety profile is well-characterized after a decade of post-marketing surveillance in the labeled HIV-lipodystrophy population. Adverse events reported in the pivotal trials and post-marketing studies include:

• Administration-site reactions. Erythema, pruritus, and induration were observed in clinical trial populations. Generally characterized as mild in trial reports.
• Hyperglycemia. Growth hormone antagonizes insulin signaling. Trials reported worsened glycemic control in some study participants; the drug label requires glucose monitoring and lists poorly controlled diabetes as a contraindication.
• Arthralgias, edema, paresthesias. Adverse events consistent with elevated IGF-1 were observed across trial cohorts.
• Theoretical oncological risk. Elevated growth-factor signaling has been associated with proliferative pathways in preclinical models. Active malignancy is a labeled contraindication; baseline cancer screening was protocol-specified in pivotal trials.
• Pituitary pathology. Listed as a contraindication; the mechanism of action requires intact pituitary function.
• Pregnancy. Listed as a contraindication in the prescribing information.

All of that safety data comes from the labeled HIV-lipodystrophy population. We found no controlled long-term safety data in any other setting. Those trials have never been run.

Cost and access in 2026

Tesamorelin is one of the most expensive prescription peptides on the US market. Egrifta SV runs $3,500-5,000 per month retail without insurance. Even with insurance, prior authorization and step therapy are common.

Coverage is limited to the FDA-approved HIV lipodystrophy indication. Off-label coverage for general metabolic disease, fatty liver, or body recomposition is essentially nonexistent.

That creates an odd dynamic. Tesamorelin has the strongest evidence in its class, but the labeled indication covers a small population: HIV patients with documented lipodystrophy. Research interest in off-label uses, mostly MASLD and general visceral fat, far exceeds the on-label market.

Off-label clinical use used to flow through compounding pharmacies. The FDA has since tightened which peptides can be compounded under section 503A. Tesamorelin's status there has shifted more than once, so check the current rule before you assume that route is open. Our guide to what a peptide clinic can and cannot prescribe sets out the limits.

third-party tested tesamorelin supplied for in-vitro work is a separate supply chain. It is appropriate for cell and animal model studies conducted in a laboratory setting, not for human use.

Regulatory status worldwide

Tesamorelin's status varies by region:

• FDA (US): Approved (Egrifta, Egrifta SV) for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. Original approval 2010, reformulated SV version 2019.
• Health Canada: Approved for the same HIV indication.
• EMA (EU): Pulled from the EU market by the sponsor in 2020. Commercial reasons, not safety.
• WADA: Banned under category S2 (peptide hormones and growth factors). Detection methods exist.
• Major sports leagues: Banned.

The EU withdrawal deserves a note. Theratechnologies pulled the drug because the European HIV-lipodystrophy market was too small to support distribution. It's not a safety signal. But European patients with the approved indication now have no pharmaceutical access.